Last reviewed · How we verify
NCT07397325
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
Phase 1, PHASE2 trial testing DA-020 in Chemotherapy Induced Alopecia in 60 participants. Not yet recruiting.
5 October 2026
Quick facts
| Lead sponsor | Applied Biology, Inc. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 16 April 2026 |
| Primary completion | 5 October 2026 |
| Estimated completion | 7 December 2026 |
| Sites | 2 locations across Italy, Brazil |
Drugs / interventions tested
- DA-020 — full drug profile →
- Placebo
- DA-020 and Hyperforin — full drug profile →
Conditions studied
- Chemotherapy Induced Alopecia — all drugs for Chemotherapy Induced Alopecia →
- Chemotherapy Side Effects — all drugs for Chemotherapy Side Effects →
Sponsor
Applied Biology, Inc. — full company profile →
Who can join
Adults 18 to 65, female only, with Chemotherapy Induced Alopecia or Chemotherapy Side Effects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07397325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chemotherapy Induced Alopecia
Currently open trials in the same condition.
- NCT07033845 — Pharmacokinetic Study of Topical Phenylephrine · EARLY_PHASE1 · recruiting
Other Applied Biology, Inc. trials
Trials by the same sponsor.
- NCT06648850 — Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth · Phase 2, PHASE3 · not yet recruiting
- NCT07402330 — Pharmacokinetic Study of DA-020 · EARLY_PHASE1 · not yet recruiting
- NCT06762548 — Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia · Phase 3 · not yet recruiting
- NCT07166354 — Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities) · Phase 1, PHASE2 · not yet recruiting
- NCT07033845 — Pharmacokinetic Study of Topical Phenylephrine · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07397325 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Applied Biology, Inc.
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07397325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing